Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort, J
by from Morbidity and Mortality Weekly Report (MMWR) on (#5X0S7)
This report describes vaccination with a primary series of the Pfizer-BioNTech mRNA COVID-19 vaccine as effective in protecting against Omicron infection among children and adolescents.